Phase I study of topotecan and cisplatin in patients with small cell lung cancer.
暂无分享,去创建一个
Hiroshi Sakai | Yutaka Nishiwaki | Takashi Seto | Y. Ichinose | Y. Nishiwaki | K. Kiura | T. Seto | M. Ando | Y. Segawa | Katsuyuki Kiura | Yukito Ichinose | Yoshihiko Segawa | H. Sakai | A. Yokoyama | Koshiro Watanabe | Akira Yokoyama | Masahiro Ando | Koshiro Watanabe
[1] L. Grochow,et al. Sequences of topotecan and cisplatin: phase I, pharmacologic, and in vitro studies to examine sequence dependence. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] G. Weiss,et al. Phase I study of daily times five topotecan and single injection of cisplatin in patients with previously untreated non-small-cell lung carcinoma. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.
[3] R. D. Hunter,et al. WHO Handbook for Reporting Results of Cancer Treatment , 1980 .
[4] A. Gouyette,et al. Phase I and pharmacokinetic study of irinotecan (CPT-11) administered daily for three consecutive days every three weeks in patients with advanced solid tumors. , 1995, Annals of oncology : official journal of the European Society for Medical Oncology.
[5] F. Hirsch,et al. A dose escalating study of topotecan preceding cisplatin in previously untreated patients with small-cell lung cancer. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.
[6] L. Grochow,et al. Cytotoxic effects of topotecan combined with various anticancer agents in human cancer cell lines. , 1996, Journal of the National Cancer Institute.
[7] N. Pavlidis,et al. Is interferon-a an active agent in Castleman's disease? , 1992, Annals of oncology : official journal of the European Society for Medical Oncology.
[8] R. Marks,et al. Current guidelines for the management of small cell lung cancer. , 1999, Mayo Clinic proceedings.
[9] C. Kurbacher,et al. Anti-neoplastic activity of topotecan versus cisplatin, etoposide and paclitaxel in four squamous cell cancer cell lines of the female genital tract using an ATP-Tumor Chemosensitivity Assay , 2000, Anti-cancer drugs.
[10] G. Rosner,et al. Phase I study of topotecan and cisplatin in patients with advanced solid tumors: a cancer and leukemia group B study. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] L. Grochow,et al. Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] W R Greco,et al. The search for cytotoxic synergy between anticancer agents: a case of Dorothy and the ruby slippers? , 1996, Journal of the National Cancer Institute.
[13] F. Schramel,et al. A randomised phase II study of the efficacy and safety of intravenous topotecan in combination with either cisplatin or etoposide in patients with untreated extensive disease small-cell lung cancer. , 2005, Lung cancer.
[14] L. Saltz,et al. Phase I clinical and pharmacology study of topotecan given daily for 5 consecutive days to patients with advanced solid tumors, with attempt at dose intensification using recombinant granulocyte colony-stimulating factor. , 1993, Journal of the National Cancer Institute.
[15] H. Hansen,et al. Phase I and pharmacokinetics study of topotecan, a new topoisomerase I inhibitor. , 1993, Annals of oncology : official journal of the European Society for Medical Oncology.
[16] G. Rosner,et al. Treatment-related fatal sepsis from topotecan/cisplatin and topotecan/paclitaxel. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] K. Mori,et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. , 2002, The New England journal of medicine.
[18] K. Suemasu,et al. Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer. , 1991, Journal of the National Cancer Institute.